Jazz Pharmaceuticals (JAZZ) Profit After Tax (2010 - 2026)

Jazz Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 416.86% year-over-year to $293.1 million; the TTM figure through Mar 2026 stood at $29.5 million (down 93.88% YoY), while the FY2025 annual figure was -$356.1 million, down 163.58% from the prior year.
• Profit After Tax was $293.1 million for Q1 2026 at Jazz Pharmaceuticals, up from $203.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $293.1 million in Q1 2026 to a low of -$718.5 million in Q2 2025.
• Historically, Profit After Tax has averaged $40.5 million across 5 years, with a median of $94.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax plunged 580.95% in 2022, then surged 4114.94% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$240.7 million in 2022, then soared by 139.11% to $94.2 million in 2023, then soared by 102.98% to $191.1 million in 2024, then grew by 6.45% to $203.5 million in 2025, then soared by 44.06% to $293.1 million in 2026.
• The last three Profit After Tax figures came in at $293.1 million (Q1 2026), $203.5 million (Q4 2025), and $251.4 million (Q3 2025), per Business Quant data.